RECRUITING

Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)

Talk to us

Conditions

Chronic Kidney Disease

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement including two Clinical Coordinating Centers (at Children's Hospital of Philadelphia and at Children's Mercy Hospital in Kansas City), a central biochemistry laboratory (at the University of Minnesota) and a Data Coordinating Center (at Johns Hopkins School of Public Health) to conduct a prospective epidemiological study of children with chronic kidney disease (CKD).

Official Title

Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)

Quick Facts

Study Start:2003-10
Study Completion:2028-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00327860

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:6 Months to 22 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age between 1 and 16 years (before 17th birthday) for Cohorts 1 and 2; age between 6 months and 16 years (before 17th birthday) for Cohort 3; age between 16 to 22 years (before 23rd birthday) for Cohort 4 and regularly seen by pediatric nephrologist prior to enrollment
  2. * Estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min\|1.73m2 for Cohort 1 OR an estimated GFR between 45 and 90 ml/min\|1.73m2 based on the updated Schwartz formula for Cohort 2; an estimated GFR ≤60 based on the CKiD Under 25 estimating equation (U25eGFR) OR KRT experience (dialysis or transplant) for Cohort 4
  3. * Willingness and ability to provide informed consent and assent
  4. * For Cohort 3, children with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.
  1. * Solid organ (other than kidney), bone marrow or stem cell transplantation
  2. * Cancer diagnosis and receiving treatment or within 12 months post completion of treatment
  3. * HIV diagnosis and receiving treatment or within 12 months post completion of treatment
  4. * Current pregnancy or pregnancy within past twelve months
  5. * Inability to complete major data collection procedures
  6. * Not fluent in English or Spanish
  7. * Plans to move out of area of any participating CKiD site (families can be transferred to another CKiD site if the family moves)
  8. * Existing moderate to severe congenital structural heart disease
  9. * Genetic syndromes involving the central nervous system (e.g., Downs syndrome)
  10. * History of severe to profound intellectual disability (i.e., Intelligence Quotient (IQ)\<40, significant impairment in adaptive function and/or inability to independently execute self-care skills)
  11. * For cohort 3, children who are expected to receive renal replacement therapy within 6 months of date of enrollment will not be recruited

Contacts and Locations

Study Contact

Susan Furth, MD, PhD
CONTACT
215-590-2449
FurthS@email.chop.edu
Bradley Warady, MD
CONTACT
816-302-3010
bwarady@cmh.edu

Principal Investigator

Susan Furth, MD, PhD
PRINCIPAL_INVESTIGATOR
Children's Hospital of Philadelphia
Bradley Warady, MD
PRINCIPAL_INVESTIGATOR
Children's Mercy Kansas City
George Schwartz, MD
PRINCIPAL_INVESTIGATOR
University of Rochester
Derek Ng, PhD
PRINCIPAL_INVESTIGATOR
Johns Hopkins Bloomberg School of Public Health
Jesse Seegmiller, PhD
PRINCIPAL_INVESTIGATOR
University of Minnesota

Study Locations (Sites)

Children's Mercy Kansas City
Kansas City, Missouri, 64108
United States
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19146
United States

Collaborators and Investigators

Sponsor: Johns Hopkins Bloomberg School of Public Health

  • Susan Furth, MD, PhD, PRINCIPAL_INVESTIGATOR, Children's Hospital of Philadelphia
  • Bradley Warady, MD, PRINCIPAL_INVESTIGATOR, Children's Mercy Kansas City
  • George Schwartz, MD, PRINCIPAL_INVESTIGATOR, University of Rochester
  • Derek Ng, PhD, PRINCIPAL_INVESTIGATOR, Johns Hopkins Bloomberg School of Public Health
  • Jesse Seegmiller, PhD, PRINCIPAL_INVESTIGATOR, University of Minnesota

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2003-10
Study Completion Date2028-07

Study Record Updates

Study Start Date2003-10
Study Completion Date2028-07

Terms related to this study

Additional Relevant MeSH Terms

  • Chronic Kidney Disease